In Depth 17 Jan 2025
Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought?
…antibody targeting PD-L1 and VEGF-A had a 69.7% overall survival rate at 18 months. While the drug overtook Keytruda in the clinic, the question remains of whether the candidate will…
